AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32816326 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital-droplet PCR (ddPCR)
Number of subjects: 37
Study 32816326 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin kappa-deleting-element (IGK-Kde) rearrangements
Number of subjects: 37
Study 32816519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacog gamma (BAX 326, Rixubis)
Number of subjects: 0
Study 32816630 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + bevacizumab
Number of subjects: 1697
Study 32816630 — intervention group
Group type: COMPARATOR
Intervention: doublets + bevacizumab
Number of subjects: 1697
Study 32816721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxfendazole oral suspension at 3, 7.5, and 15 mg/kg once daily for 5 days
Number of subjects: 36
Study 32816721 — intervention group
Group type: COMPARATOR
Intervention: Single 3 mg/kg dose of oxfendazole after overnight fast
Number of subjects: 36
Study 32816721 — intervention group
Group type: COMPARATOR
Intervention: Single 3 mg/kg dose of oxfendazole after consumption of a fatty breakfast
Number of subjects: 36
Study 32816723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole treatment, dosage not specified, duration not specified
Number of subjects: 0
Study 32816723 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32816724 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin in ECMO patients
Number of subjects: 19
Study 32816724 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin in non-ECMO patients
Number of subjects: 19
Study 32816724 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin before ECMO weaning
Number of subjects: 19
Study 32816724 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin after ECMO weaning
Number of subjects: 19
Study 32816724 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 19
Study 32816849 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) analysis
Number of subjects: 0
Study 32816849 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint blockade
Number of subjects: 0
Study 32816891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Number of subjects: 84
Study 32816893 — intervention group
Group type: EXPERIMENTAL
Intervention: AA patients
Number of subjects: 331
Study 32816893 — intervention group
Group type: COMPARATOR
Intervention: Non-AA cohort
Number of subjects: 331
Study 32816892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocimagene amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC)
Number of subjects: 0
Study 32816951 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI0562 (0.03, 0.1, 0.3, 1.0, 3.0, or 10 mg/kg) administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
Number of subjects: 55
Study 32816951 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI0562 (0.03, 0.1, 0.3, 1.0, 3.0, or 10 mg/kg) administered intravenously every 2 weeks.
Number of subjects: 55
Study 32816955 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness resection (EFTR)
Number of subjects: 0
Study 32816955 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopic resection (SER)
Number of subjects: 0
Study 32816955 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 0
Study 32816955 — intervention group
Group type: COMPARATOR
Intervention: Pooled alternative treatment to EFTR
Number of subjects: 0
Study 32817006 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Number of subjects: 0
Study 32817060 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKi as first-line treatment
Number of subjects: 365
Study 32817060 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKi as second-line treatment
Number of subjects: 365
Study 32817060 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKi as third-line treatment and beyond
Number of subjects: 365
Study 32817060 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKi treatment
Number of subjects: 365
Study 32817079 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 38
Study 32817288 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg, two weeks apart) combined with belimumab (10 mg/kg at week 0, W0+2 days, W2+2 days, W4, W8, and W12)
Number of subjects: 15
Study 32817288 — intervention group
Group type: COMPARATOR
Intervention: Rituximab alone (comparison group)
Number of subjects: 15
Study 32817460 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum LIGHT levels in hospitalized COVID-19 patients
Number of subjects: 0
Study 32817460 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on and off ventilatory support
Number of subjects: 0
Study 32817460 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients over the age of 60
Number of subjects: 0
Study 32817593 — intervention group
Group type: EXPERIMENTAL
Intervention: H3.3K27M-targeted peptide vaccine administered with poly-ICLC every 3 weeks for 8 cycles, then every 6 weeks.
Number of subjects: 29
Study 32817593 — intervention group
Group type: EXPERIMENTAL
Intervention: H3.3K27M-targeted peptide vaccine with observed immunological responses.
Number of subjects: 29
Study 32817593 — intervention group
Group type: EXPERIMENTAL
Intervention: H3.3K27M-targeted peptide vaccine in patients with below-median baseline levels of myeloid-derived suppressor cells.
Number of subjects: 29
Study 32817593 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pretreatment dexamethasone administration.
Number of subjects: 29
Study 32817749 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate Diet (VLCD)
Number of subjects: 34
Study 32817749 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 34
Study 32817798 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer values for inactivity (<1.5 METs)
Number of subjects: 22
Study 32817798 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer values for MVPA (≥3.0 METs)
Number of subjects: 22
Study 32817798 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured METs during standing and walking activities
Number of subjects: 22
Study 32817978 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion within 3 days of COVID-19 diagnosis
Number of subjects: 35322
Study 32817978 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion 4 or more days after COVID-19 diagnosis
Number of subjects: 35322
Study 32817978 — intervention group
Group type: EXPERIMENTAL
Intervention: High IgG plasma (>18.45 S/Co)
Number of subjects: 35322
Study 32817978 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium IgG plasma (4.62 to 18.45 S/Co)
Number of subjects: 35322
Study 32817978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low IgG plasma (<4.62 S/Co)
Number of subjects: 35322
Study 32817978 — intervention group
Group type: EXPERIMENTAL
Intervention: High antibody level plasma units
Number of subjects: 35322
Study 32818157 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day challenge with penicillin
Number of subjects: 305
Study 32818157 — intervention group
Group type: COMPARATOR
Intervention: Single full dose of penicillin
Number of subjects: 305
Study 32818236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ter allele of Rs752074397 in DAO
Number of subjects: 373
Study 32818460 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral antibiotics
Number of subjects: 0
Study 32818466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 43
Study 32818917 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK) plus oral antidepressant (OAD)
Number of subjects: 23
Study 32819275 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fasting plasma glucose (FPG)
Number of subjects: 7762
Study 32819275 — intervention group
Group type: COMPARATOR
Intervention: Normal fasting plasma glucose (FPG)
Number of subjects: 7762
Study 32819310 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive gestational weight gain
Number of subjects: 124
Study 32819310 — intervention group
Group type: COMPARATOR
Intervention: Adequate gestational weight gain
Number of subjects: 124
Study 32819310 — intervention group
Group type: COMPARATOR
Intervention: Insufficient gestational weight gain
Number of subjects: 124
Study 32819310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain categories
Number of subjects: 124
Study 32819311 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-based scoring system (paper-based questionnaire) during and up to 24 weeks following radiotherapy.
Number of subjects: 98
Study 32819311 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diagnostic procedures if radiation pneumonitis is suspected.
Number of subjects: 98
Study 32819311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application functionality testing in 10 patients in addition to the paper-based questionnaire.
Number of subjects: 98
Study 32819400 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 527
Study 32819400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 6.8 mL/kg
Number of subjects: 527
Study 32819400 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) of 8 cmH2O
Number of subjects: 527
Study 32819400 — intervention group
Group type: COMPARATOR
Intervention: Incidence of ARDS
Number of subjects: 527
Study 32819400 — intervention group
Group type: COMPARATOR
Intervention: Mortality and withdrawal of life-sustaining care
Number of subjects: 527
Study 32819400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective strategy compliance
Number of subjects: 527
Study 32819400 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct treatment
Number of subjects: 527
Study 32819449 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 64
Study 32819469 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrecognized myocardial infarction (UMI)
Number of subjects: 2349
Study 32819469 — intervention group
Group type: COMPARATOR
Intervention: Recognized myocardial infarction (RMI)
Number of subjects: 2349
Study 32819481 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR >0.80
Number of subjects: 588
Study 32819481 — intervention group
Group type: COMPARATOR
Intervention: Post-PCI FFR ≤0.80
Number of subjects: 588
Study 32819481 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI Pd/Pa >0.92
Number of subjects: 588
Study 32819481 — intervention group
Group type: COMPARATOR
Intervention: Post-PCI Pd/Pa ≤0.92
Number of subjects: 588
Study 32819481 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI Pd/Pa ≤0.92 and FFR ≤0.80
Number of subjects: 588
Study 32819481 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI Pd/Pa ≤0.92 but FFR >0.80
Number of subjects: 588
Study 32819531 — intervention group
Group type: EXPERIMENTAL
Intervention: THERMOCOOL SMARTTOUCH SF Catheter
Number of subjects: 381
Study 32819881 — intervention group
Group type: EXPERIMENTAL
Intervention: R2V2 (Vorinostat plus Bortezomib, Lenalidomide, and Dexamethasone)
Number of subjects: 30
Study 32819883 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA24 recalls
Number of subjects: 1077
Study 32819883 — intervention group
Group type: COMPARATOR
Intervention: 4DFRs
Number of subjects: 1077
Study 32819883 — intervention group
Group type: COMPARATOR
Intervention: FFQs
Number of subjects: 1077
Study 32819953 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of fathers in care-seeking processes for sick children
Number of subjects: 24
Study 32819953 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial responsibility for child healthcare
Number of subjects: 24
Study 32819953 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of health services
Number of subjects: 24
Study 32819953 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing perceptions of paternal responsibilities
Number of subjects: 24
Study 32819957 — intervention group
Group type: EXPERIMENTAL
Intervention: COpenhagen ROsacea COhort (COROCO)
Number of subjects: 0
Study 32819957 — intervention group
Group type: EXPERIMENTAL
Intervention: COpenhagen MIgraine COhort (COMICO)
Number of subjects: 0
Study 32819972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg every 3 weeks for four doses combined with radiotherapy (9, 15, 18, and 24 Gy) at week 4.
Number of subjects: 19
Study 32819972 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with ipilimumab.
Number of subjects: 19
Study 32819972 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (9 Gy) combined with ipilimumab.
Number of subjects: 19
Study 32819972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg every 12 weeks for maintenance after week 24 for patients with clinical benefit.
Number of subjects: 19
Study 32819972 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned).
Number of subjects: 19
Study 32819975 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS) combined with gemcitabine (GEM); specific dosage and duration not mentioned.
Number of subjects: 0
Study 32819975 — intervention group
Group type: COMPARATOR
Intervention: Focused ultrasound (FUS) monotherapy; specific dosage and duration not mentioned.
Number of subjects: 0
Study 32819975 — intervention group
Group type: EXPERIMENTAL
Intervention: FUS+GEM with either neoadjuvant or adjuvant treatment with anti-PD-1; specific dosage and duration not mentioned.
Number of subjects: 0
Study 32819989 — intervention group
Group type: COMPARATOR
Intervention: Gingival inflammation (BOP ≥30%)
Number of subjects: 1394
Study 32819989 — intervention group
Group type: COMPARATOR
Intervention: Gingival inflammation (BOP ≥30%) in first trimester
Number of subjects: 1394
Study 32819989 — intervention group
Group type: COMPARATOR
Intervention: Gingival inflammation (BOP ≥30%) later in pregnancy
Number of subjects: 1394
Study 32819989 — intervention group
Group type: COMPARATOR
Intervention: Mild periodontitis
Number of subjects: 1394
Study 32819989 — intervention group
Group type: COMPARATOR
Intervention: Overall preterm birth incidence
Number of subjects: 1394
Study 32819996 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy (MIRH)
Number of subjects: 2800
Study 32819996 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (ARH)
Number of subjects: 2800
Study 32820223 — intervention group
Group type: EXPERIMENTAL
Intervention: Metalloproteinase (MMP)-9 expression in AT
Number of subjects: 103
Study 32820223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue inhibitor of MMP (TIMP)-1 expression in AT
Number of subjects: 103
Study 32820223 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen activator inhibitor (PAI)-1 expression in AT
Number of subjects: 103
Study 32820223 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity measured by glucose clamp technique
Number of subjects: 103
Study 32820369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretargeted immuno-PET using anti-CEA recombinant bispecific monoclonal antibody (BsMAb) TF2 and gallium-68-labelled IMP-288 peptide
Number of subjects: 11
Study 32820369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretargeted immuno-PET
Number of subjects: 11
Study 32820369 — intervention group
Group type: EXPERIMENTAL
Intervention: BsMAb and peptide injections
Number of subjects: 11
Study 32820452 — intervention group
Group type: EXPERIMENTAL
Intervention: β-glucan, 200 mg/day for 8 weeks
Number of subjects: 37
Study 32820452 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic model for PQD risk score
Number of subjects: 37
Study 32820453 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Chinese and Western medicine (ICM) group receiving CM herbal treatment combined with Western medicine (WM) anti-tumor therapy
Number of subjects: 384
Study 32820453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) group receiving only CM herbal treatment
Number of subjects: 384
Study 32820453 — intervention group
Group type: COMPARATOR
Intervention: WM group receiving only WM anti-tumor therapy
Number of subjects: 384
Study 32820536 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 6894
Study 32820536 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 6894
Study 32820618 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine concentrations in type 2 diabetes patients
Number of subjects: 35
Study 32820618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocellular lipid concentrations in type 2 diabetes patients
Number of subjects: 35
Study 32820618 — intervention group
Group type: COMPARATOR
Intervention: Intramyocellular lipids
Number of subjects: 35
Study 32820618 — intervention group
Group type: COMPARATOR
Intervention: Acetylcarnitine
Number of subjects: 35
Study 32821007 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum concentrations of GFAP
Number of subjects: 145
Study 32821007 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum concentrations of UCH-L1
Number of subjects: 145
Study 32821164 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib monotherapy
Number of subjects: 737
Study 32821164 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combination therapy
Number of subjects: 737
Study 32821164 — intervention group
Group type: COMPARATOR
Intervention: Apatinib (both monotherapy and combination)
Number of subjects: 737
Study 32821287 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin triple therapy with add-on NAC
Number of subjects: 680
Study 32821287 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin triple therapy alone
Number of subjects: 680
Study 32821419 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dinoprostone (Propess)
Number of subjects: 274
Study 32821419 — intervention group
Group type: COMPARATOR
Intervention: Cervical ripening balloon catheter (CRB)
Number of subjects: 274
Study 32821422 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of medication (SAM) during hospitalization
Number of subjects: 60
Study 32821422 — intervention group
Group type: COMPARATOR
Intervention: Nurse-led dispensing (Control)
Number of subjects: 60
Study 32821712 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 g/day) plus statin
Number of subjects: 56
Study 32821712 — intervention group
Group type: COMPARATOR
Intervention: Statin only
Number of subjects: 56
Study 32821737 — intervention group
Group type: EXPERIMENTAL
Intervention: New generic rosuvastatin 10 mg daily for 8 weeks
Number of subjects: 126
Study 32821737 — intervention group
Group type: COMPARATOR
Intervention: Proprietary rosuvastatin 10 mg daily for 8 weeks
Number of subjects: 126
Study 32821737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 126
Study 32822476 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomographic Angiography (CCTA)
Number of subjects: 612
Study 32822476 — intervention group
Group type: COMPARATOR
Intervention: Myocardial Perfusion Imaging
Number of subjects: 612
Study 32822476 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive FFR measurement
Number of subjects: 612
Study 32822482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib, dexamethasone, and rituximab (IDR)
Number of subjects: 26
Study 32822634 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA1 mutation carriers
Number of subjects: 252
Study 32822634 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA2 mutation carriers
Number of subjects: 252
Study 32822634 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA3 mutation carriers
Number of subjects: 252
Study 32822634 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA6 mutation carriers
Number of subjects: 252
Study 32822634 — intervention group
Group type: COMPARATOR
Intervention: SCA1 non-carriers
Number of subjects: 252
Study 32822634 — intervention group
Group type: COMPARATOR
Intervention: SCA2 non-carriers
Number of subjects: 252
Study 32822675 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic bronchoscopy with radial probe endobronchial ultrasound (R-EBUS) imaging
Number of subjects: 54
Study 32822675 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic bronchoscopy
Number of subjects: 54
Study 32823563 — intervention group
Group type: EXPERIMENTAL
Intervention: CDN MK-1454
Number of subjects: 0
Study 32823563 — intervention group
Group type: EXPERIMENTAL
Intervention: CDN ADU-S100
Number of subjects: 0
Study 32823781 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium screening tools used in patients with varying sedation levels and ventilation status.
Number of subjects: 0
Study 32824065 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake (mean 82.2 ± 21.3 g/d)
Number of subjects: 730
Study 32824065 — intervention group
Group type: COMPARATOR
Intervention: Moderate fatigue (CIS score 20-34)
Number of subjects: 730
Study 32824065 — intervention group
Group type: COMPARATOR
Intervention: Severe fatigue (CIS score ≥ 35)
Number of subjects: 730
Study 32824065 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) assessed with RAND-36
Number of subjects: 730
Study 32824392 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor resection (PTR) followed by chemotherapy
Number of subjects: 48
Study 32824392 — intervention group
Group type: COMPARATOR
Intervention: Upfront chemotherapy alone
Number of subjects: 48
Study 32825827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternal reconstruction using titanium plates
Number of subjects: 5
Study 32826283 — intervention group
Group type: EXPERIMENTAL
Intervention: ASQ (Ask Suicide-Screening Questions)
Number of subjects: 600
Study 32826289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation attendees
Number of subjects: 4570
Study 32826289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation attendees who were physically active ≥150 min/week
Number of subjects: 4570
Study 32826289 — intervention group
Group type: COMPARATOR
Intervention: Cardiac rehabilitation
Number of subjects: 4570
Study 32826289 — intervention group
Group type: COMPARATOR
Intervention: Self-reported physical activity of ≥150 min/week
Number of subjects: 4570
Study 32826449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable angina
Number of subjects: 49
Study 32826449 — intervention group
Group type: COMPARATOR
Intervention: NSTEMI
Number of subjects: 49
Study 32826449 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49